AbbVie

News

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.

News

AbbVie closes on Rinvoq approval in inflamed artery disease

AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.

News

FDA clears new antibiotic for superbug infections

AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.

R&D

JPM25 Steve Pakola interview with Jonah Comstock

JP Morgan Week 2025 – Steve Pakola

On the sidelines of JP Morgan in San Francisco, editor-in-chief Jonah Comstock caught up with Steven Pakola, REGENXBIO’s chief medical officer.

News

AbbVie adds psoriasis med with Nimble takeover

AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline.

News

AbbVie bags EU nod for key drug from ImmunoGen takeover

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie closes on Rinvoq approval in inflamed artery disease

FDA clears new antibiotic for superbug infections

JP Morgan Week 2025 – Steve Pakola

AbbVie adds psoriasis med with Nimble takeover

AbbVie bags EU nod for key drug from ImmunoGen takeover

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks